Search Results for "Silenor"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Silenor. Results 1 to 7 of 7 total matches.
See also: doxepin

Low-Dose Doxepin (Silenor) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2010  (Issue 1348)
Low-Dose Doxepin (Silenor) for Insomnia ...
The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin (Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this dose retains the hypnotic effect of doxepin, without typical tricyclic adverse effects. Doxepin is available generically in higher-strength capsules and in a liquid formulation.
Med Lett Drugs Ther. 2010 Oct 4;52(1348):79-80 |  Show IntroductionHide Introduction

In Brief: Off-Label Amitriptyline for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023  (Issue 1672)
antidepressant doxepin (Silenor, and generics) is FDA-approved for treatment of sleep-maintenance insomnia ...
In our article on Drugs for Chronic Insomnia, we said there is little evidence that antidepressants such as trazodone, mirtazapine, or amitriptyline are effective in treating insomnia not associated with depression. We received a comment from a reader who has prescribed the tricyclic antidepressant amitriptyline for insomnia, particularly for patients with headache disorders, and finds that most patients are satisfied with the treatment.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):48   doi:10.58347/tml.2023.1672d |  Show IntroductionHide Introduction

Suvorexant (Belsomra) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
agonist ramelteon (Rozerem, and generics), and low doses of the antidepressant doxepin (Silenor ...
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31 |  Show IntroductionHide Introduction

Lemborexant (Dayvigo) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
antidepressant doxepin in low doses (Silenor, and generics), or suvorexant may be more effective, but they can ...
The FDA has approved lemborexant (Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) was the first.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):97-100 |  Show IntroductionHide Introduction

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
, and generics), extended-release zolpidem, low-dose doxepin (Silenor, and generics), or an orexin receptor ...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 |  Show IntroductionHide Introduction

Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
Cost3 Some Adverse Effects Comments Tricyclic Antidepressant Doxepin – generic Silenor (Pernix ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10   doi:10.58347/tml.2023.1667b |  Show IntroductionHide Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
tabs 30 min long 3-6 mg15 3 mg15 349.20 Silenor (Pernix) 538.80 ER = extended-release; SL ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a |  Show IntroductionHide Introduction